Retinal diseases contributing heavily to the demand growth of intravitreal (IVT) injectables
Hereditary retinal diseases is the major cause of visual loss. Macular degeneration, Diabetic Retinopathy is the important and prominent cause of blindness.
According to Genentech Retinal disease report, around 11 million US population are affected with age-related macular degeneration, 7.7 million people are affected with diabetic retinopathy and around 1.1 million population are affected with retinal vein occlusions.
North America to have substantial revenue growth in intravitreal (IVT) injectables Market
North America region shown to have high growth in intravitreal (IVT) injectables market. Low vision and blindness are prevailing in the region and high prescription of anti-VEGF intravitreal (IVT) injectables medication has increases the growth of intravitreal (IVT) injectables market. It is estimated that intravitreal (IVT) injectables create an incremental $ opportunity worth US$ 4,350 Mn between 2018 and 2028.
Lucentis marketed by Roche and Eylea marketed by Regeneron in the United States, are the commonly prescribed biologics use in intravitreal (IVT) injectables. Apart from this, Avastin and Macugen are also widely used in intravitreal (IVT) injectables market.
The North America region holds a significant share in intravitreal (IVT) injectables among all other regions, due to the increase in prescription of retinal biologics, high healthcare facilities and availability and usage of expensive drugs.
The global intravitreal (IVT) injectables market has been segmented on the basis of drug class, indication and distributional channel. On the basis of drug class, the intravitreal (IVT) injectables market has been segmented into anti-VEGF, corticosteroids, antibiotics, antivirals and antifungals. Based on indication, the intravitreal (IVT) injectables market has been segmented into diabetic retinopathy, macular degeneration, endophthalmitis, retinal vein occlusions and others.
In terms of revenue, the anti-VEGF segment is expected to have a major share in intravitreal (IVT) injectables during the forecast period as it prevents angiogenesis and also minimize the leakage of fluid that occurs due to retinal diseases.
On the basis of distributional channel, the intravitreal (IVT) injectables market has been categorized into hospital pharmacies, retail pharmacies, drug stores, mail order pharmacies and others. The hospital pharmacies is expected to have high revenue growth in intravitreal (IVT) injectables, owing to the availability of biologics and increase in prescription of anti-VEGF drugs.
Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.
Ashish Kolte Persistence Market Research Address – 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – [email protected] Website – https://www.persistencemarketresearch.com